What is ARA-290?
ARA-290 (Cibinetide) is an 11-amino acid synthetic peptide derived from the helix B surface peptide (HBSP) of erythropoietin (EPO). Unlike EPO itself, ARA-290 selectively activates the innate repair receptor (IRR) — a heterodimeric complex of the EPO receptor and the beta common receptor (βcR) — without engaging the classical homodimeric EPO receptor responsible for erythropoiesis. This separation of tissue-protective signalling from haematopoietic activity makes ARA-290 a focused research tool for studying EPO’s non-erythroid cytoprotective and anti-inflammatory properties.
Research Applications
Mechanism of Action
ARA-290 binds the IRR (a heterodimer of EPO receptor subunit + βcR subunit), triggering a distinct intracellular signalling cascade from classical EPO. Downstream activates PI3K/Akt (cell survival), JAK2/STAT3 (anti-apoptotic gene expression), and MAPK/ERK (cell proliferation) pathways. Critically, does not activate the EPOR homodimer, so does not stimulate erythropoiesis, haemoglobin synthesis, or platelet aggregation risk associated with exogenous EPO administration.
Key Research Data
| Phase 2 RCT (Sarcoidosis SFN) | N=55; ARA-290 4mg SC × 28 days vs placebo. Primary endpoint: corneal nerve fibre density (CNFD). Result: significant CNFD preservation + pain NRS reduction (p<0.05) |
| Pancreatic islet study | Human islets treated with IL-1β + IFN-γ; ARA-290 rescued GSIS, reduced apoptosis markers (caspase-3), reduced TNF-α secretion |
| Rodent ischaemia model | ARA-290 SC pre-treatment reduced renal tubular injury scores 40-60% vs vehicle in I/R models (rat) |
| Selectivity vs EPO | No haematopoietic effect confirmed across multiple studies: haematocrit, haemoglobin, reticulocyte count unchanged at research doses |
Quick Specs
| Brand | Anti-Aging & Longevity |
